- Home
- MMLP vs PLX Comparison
MMLP vs PLX Comparison
Compare MMLP & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMLP
- PLX
- Stock Information
- Founded
- MMLP 2002
- PLX 1993
- Country
- MMLP United States
- PLX United States
- Employees
- MMLP N/A
- PLX N/A
- Industry
- MMLP Oil Refining/Marketing
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMLP Energy
- PLX Health Care
- Exchange
- MMLP Nasdaq
- PLX Nasdaq
- Market Cap
- MMLP 139.6M
- PLX 122.6M
- IPO Year
- MMLP 2002
- PLX 1998
- Fundamental
- Price
- MMLP $3.10
- PLX $1.40
- Analyst Decision
- MMLP
- PLX Strong Buy
- Analyst Count
- MMLP 0
- PLX 1
- Target Price
- MMLP N/A
- PLX $15.00
- AVG Volume (30 Days)
- MMLP 72.2K
- PLX 640.7K
- Earning Date
- MMLP 07-16-2025
- PLX 08-13-2025
- Dividend Yield
- MMLP 0.65%
- PLX N/A
- EPS Growth
- MMLP N/A
- PLX N/A
- EPS
- MMLP N/A
- PLX 0.05
- Revenue
- MMLP $719,335,000.00
- PLX $59,764,000.00
- Revenue This Year
- MMLP $4.19
- PLX $65.02
- Revenue Next Year
- MMLP N/A
- PLX $57.34
- P/E Ratio
- MMLP N/A
- PLX $28.96
- Revenue Growth
- MMLP N/A
- PLX 0.18
- 52 Week Low
- MMLP $2.56
- PLX $0.82
- 52 Week High
- MMLP $4.13
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- MMLP 50.73
- PLX 30.38
- Support Level
- MMLP $3.02
- PLX $1.52
- Resistance Level
- MMLP $3.47
- PLX $1.65
- Average True Range (ATR)
- MMLP 0.18
- PLX 0.08
- MACD
- MMLP 0.00
- PLX 0.02
- Stochastic Oscillator
- MMLP 32.73
- PLX 17.19
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.